Today's Peptide News — August 13, 2026

A new bioRxiv preprint describes a structure-guided pipeline that yields peptide inhibitors targeting the secreted peptidases that drug-resistant fungi use to invade tissue and evade the immune system. Rather than trying to kill the fungus outright, the designed peptides block the enzymes that drive virulence and resistance, exhibiting potent antifungal activity while leaving mammalian cells unharmed.

The authors report that the peptidase inhibitors produced additive effects when combined with existing antifungal drugs and showed no host-cell cytotoxicity in their assays. That combination of selectivity and drug synergy is the crux of the finding, because the toxicity and narrow spectrum of current antifungals is one of the biggest gaps in infectious-disease medicine.

Why it matters: invasive fungal infections are rising and resistance to the small number of available antifungals is spreading, so a rationally designed, low-toxicity peptide scaffold that disarms virulence is a genuinely fresh angle. For PeptideWiki, a short post could frame this as "anti-virulence" peptides — a strategy that disables the pathogen's weapons instead of poisoning it — and use it to explain why targeting secreted peptidases may slow the emergence of resistance.

A real-world retrospective cohort study indexed on PubMed compared patients with type 2 diabetes who started tirzepatide, the dual GIP/GLP-1 receptor agonist, against those who started semaglutide. Patients initiating tirzepatide had markedly lower relative risks of mild cognitive impairment, dementia, and Alzheimer's disease over follow-up, with reported relative risks of roughly 0.12, 0.15, and 0.48 respectively.

The signal is notable because it lands against a mixed backdrop: the large EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in early symptomatic Alzheimer's disease did not show a statistically significant benefit on the primary cognitive endpoint. A cohort study cannot prove causation the way a randomized trial can, and confounding by indication is a real limitation, but the magnitude of the difference between two closely related incretin drugs is striking.

Why it matters: it hints that dual GIP/GLP-1 agonism may protect the aging brain more than GLP-1 alone, a mechanistic question that matters well beyond diabetes. For PeptideWiki, the angle is a head-to-head framing — tirzepatide versus semaglutide on brain health — paired with a clear caveat that this is observational data awaiting confirmation from dedicated trials.

MOTS-c, the 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region, is moving from preclinical hype into a controlled human study. A 2026 Phase 2a trial (NCT07505745) is testing whether MOTS-c changes insulin sensitivity in adults with prediabetes who are overweight or obese, with the primary endpoint being change from baseline in OGTT-derived insulin sensitivity measured by the Matsuda Index.

Mechanistically, MOTS-c activates AMP-activated protein kinase, enhances insulin sensitivity, stimulates fatty-acid oxidation, and improves glucose utilization. Recent work indicates it does this in part by disrupting the de novo purine synthesis arm of the folate cycle, causing AICAR to accumulate and drive AMPK activation in skeletal muscle. Until now, most of the compelling data have come from cell and animal models, so a randomized human trial with an objective metabolic endpoint is a meaningful step.

Why it matters: mitochondrial-derived peptides are one of the most-discussed and least-validated corners of the peptide world, and a rigorous prediabetes trial is exactly the kind of evidence the field needs. For PeptideWiki, this is a natural update to the MOTS-c entry — a short post explaining what the Matsuda Index measures, what the trial can and cannot prove, and why it separates genuine clinical promise from marketing.

Novo Nordisk reported Phase 2 results for zenagamtide, described as the first single-molecule drug to combine GLP-1 and amylin receptor activation in one compound. The trial showed meaningful glucose and weight effects in type 2 diabetes, positioning the molecule as a next step beyond the company's existing GLP-1 franchise and its separate cagrilintide-plus-semaglutide combination.

Combining GLP-1 and amylin activity has been a long-standing goal because the two hormones curb appetite and regulate glucose through complementary pathways, and folding both into a single peptide simplifies dosing and manufacturing compared with a two-drug cocktail. The result adds to a rapidly crowding metabolic-peptide field where multi-receptor agonism is becoming the dominant design theme.

Why it matters: it signals that the industry is moving past single-hormone GLP-1 drugs toward unified multi-agonists, which could reshape the obesity and diabetes market. For PeptideWiki, a brief post could introduce amylin as the "other" satiety hormone and explain why co-agonism in one molecule is engineering-hard but commercially attractive.

Eli Lilly's retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors, is heading toward its pivotal Phase 3 obesity readout in TRIUMPH-1 in the second half of 2026. If the earlier Phase 2 efficacy of roughly 24% mean weight loss holds up, retatrutide would set a new benchmark for anti-obesity pharmacotherapy, and Lilly reportedly has several additional Phase 3 readouts across dose levels and indications queued for the year.

The triple-agonist approach adds glucagon-receptor activity to the now-familiar GLP-1/GIP combination, which is thought to increase energy expenditure on top of appetite suppression. That extra mechanism is what analysts credit for the unusually large weight-loss numbers seen in mid-stage trials.

Why it matters: the weight-loss ceiling for peptide drugs keeps rising, and retatrutide is the leading test of whether triple agonism can push efficacy toward the range once reserved for bariatric surgery. For PeptideWiki, the angle is a "how many receptors is too many" explainer that walks readers from single to dual to triple agonists and what each added target buys.

Sethera Therapeutics, a US biotech, is developing technology aimed at letting peptide drugs be taken as pills by stabilizing them so they survive digestion. In partnership with the University of Utah, the company has produced an enzyme-based platform designed to simplify peptide synthesis and shorten development timelines, with the approach currently in preclinical testing.

Oral delivery has long been the Achilles' heel of peptide therapeutics: the gut degrades most peptides before they can be absorbed, which is why so many are still injectables. Approaches that either armor the peptide or streamline its manufacture speak directly to the two costs that keep peptide drugs expensive and inconvenient.

Why it matters: needle-free peptides would dramatically widen access to a class of drugs now dominated by injections, and manufacturing innovation is quietly as important as any new molecule. For PeptideWiki, a short post could explain why the stomach is so hostile to peptides and survey the main strategies — enzyme stabilization, permeation enhancers, and chemical modification — being used to get them past it.

Researchers report a wearable patch that helps people reach REM sleep faster and stay in it longer without medication or surgery. In a small study of 28 participants, the device shortened the time to REM by about 43 minutes and extended time spent in that stage by roughly 16 minutes.

REM sleep is closely tied to memory consolidation and emotional processing, and pharmacological sleep aids often suppress it, so a non-drug method of nudging the brain into REM is an unusual and welcome direction. The sample is small and needs replication, but the effect sizes are large enough to be interesting.

Why it matters: if it holds up, a drug-free wearable could help people with REM-deprived sleep without the downsides of sedatives, a meaningful option for a population increasingly wary of sleep medications.

A prescription form of THC helped many people with post-traumatic stress disorder escape recurring trauma-related nightmares, with more than a third of participants reporting that the nightmares disappeared completely after ten weeks of treatment. The finding adds to a growing body of work on cannabinoid approaches to trauma-related sleep disruption.

Nightmares are one of the most persistent and distressing symptoms of PTSD and are often resistant to standard therapy. A treatment that fully clears them in a substantial minority of patients would be clinically significant, though questions about dependence, daytime effects, and durability remain.

Why it matters: it strengthens the case for regulated cannabinoid therapeutics in psychiatry, an area where evidence has often lagged behind public enthusiasm. This is a sensitive mental-health topic; anyone affected should discuss options with a qualified clinician rather than self-treating.

New research indicates that beginning around age 50, the hippocampus — the brain's memory center — loses many of its long-resident immune cells and replaces them with more inflammatory ones. The shift points to a specific cellular turnover that may help explain why memory becomes more vulnerable with age.

The brain's resident immune cells, microglia, normally maintain and protect neural tissue, so a mid-life change toward a more inflammatory population could set the stage for cognitive decline and neurodegenerative disease. Identifying when and where that switch happens gives researchers a concrete window to target.

Why it matters: pinning the change to a particular decade and brain region offers a potential intervention point, and it dovetails with the growing interest in whether metabolic drugs like GLP-1 agonists can dampen brain inflammation and protect memory with age.